Gilead Sciences (GILD) 105.93 $GILD
Most active Nasdaq-traded stocks
AP - 1 hr 39 mins ago
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - 1 hr 39 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 9 mins ago
Sanofi (SNY) announced that it has entered into an agreement with MyoKardia, Inc. to discover and develop targeted therapeutics for cardiomyopathies.
Bayer/Orion Progress with Prostate Cancer Drug ODM-201 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 29 mins ago
Bayer (BAYRY) and Orion Corp. announced that they have started enrolling patients for a phase III study on ODM-201.
Alnylam (ALNY) to File Clinical Trial Application for ALN-CC5 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 34 mins ago
Alnylam Pharmaceuticals (ALNY) intends to file a clinical trial application for ALN-CC5 by year end.
Gilead Down on Weak Simtuzumab Data and Sovaldi News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:16PM CDT
Shares of Gilead (GILD) were down following a couple of setbacks.
Midday Glance: Biotechnology companies
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Is It Time to Buy Dividend Stock Bristol-Myers Squibb Co?
George Budwell, The Motley Fool - Motley Fool - Thu Sep 18, 9:57AM CDT
Big Pharma's battle with the patent cliff has led to drastic changes across the healthcare sector. Companies have slashed workforces, changed the focus of their product and clinical portfolios, and even moved abroad to lower their effective tax...
ImmunoCellular Therapeutics (IMUC) Jumps: Stock Up 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:58AM CDT
ImmunoCellular Therapeutics, Ltd. (IMUC) was a big mover last session, as its shares rose nearly 9% on the day.
Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:39AM CDT
Halozyme Therapeutics, Inc. (HALO) was a big mover last session, as its shares rose over 9% on the day.
Repros Therapeutics (RPRX) Crumbles: Stock Falls by 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:51AM CDT
Repros Therapeutics Inc. (RPRX) saw a big move last session,continuing the recent downtrend for RPRX, as the stock is now down more than 11.5% in the past one-month time frame.
Gilead Sciences, inc. Stock's Incoming Game Changer
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 18, 7:45AM CDT
Gilead Sciences ' Sovaldi may have revolutionized hepatitis C treatment, but it also served as a lightning rod of controversy over drugmakers' pricing of next-generation medicines. Sovaldi's ability to clear the virus in 90% of patients over 12...
3 Best Stocks for Investing in Biotech
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 18, 7:35AM CDT
Few baskets are as hit-and-miss as biotech. The group is notoriously fickle and maddeningly volatile -- and for good reason. Whims and whispers tied to the latest clinical trial results can move biotech stocks in fits and starts, making them best...
Market Maker Surveillance Report. EPGL, CMCSA, GILD, YHOO, MSFT, VALE, Bearishly Biased Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:25AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. EP GLOBAL COMMUNICATIONS INC (OTC:EPGL), Comcast Corp (NASDAQ:CMCSA), GILEAD SCIENCES, INC. (NASDAQ:GILD), Yahoo! Inc (NASDAQ:YHOO), MICROSOFT CORPORATION (NASDAQ:MSFT), Vale SA (NYSE:VALE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Jim Cramer's 'Mad Money' Recap: Hooray for the Federal Reserve
at The Street - Wed Sep 17, 7:08PM CDT
Now that the Fed has done the right thing on monetary policy, investors should stop worrying and start thinking about how to make more money, Cramer says.
Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:15PM CDT
Merck & Co. Inc. (MRK) announced encouraging data from a pivotal phase III fracture outcomes study evaluating the use of odanacatib in postmenopausal women suffering from osteoporosis.
Shire's Vyvanse Accepted for FDA Review for Binge Eating - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:00PM CDT
Shire plc (SHPG) recently announced that the FDA has accepted its filing with priority review a supplemental New Drug Application (sNDA) for Vyvanse for treating adults with binge eating disorder.
UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:40PM CDT
UCB SA (UCBJF) and Amgen announced positive results from exploratory analyses of a phase II study on romosozumab in postmenopausal women with low bone mineral density.
Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 4:05PM CDT
Abbott Labs (ABT) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb.
Most active Nasdaq-traded stocks
AP - 1 hr 39 mins ago
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - 1 hr 39 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 9 mins ago
Sanofi (SNY) announced that it has entered into an agreement with MyoKardia, Inc. to discover and develop targeted therapeutics for cardiomyopathies.
Bayer/Orion Progress with Prostate Cancer Drug ODM-201 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 29 mins ago
Bayer (BAYRY) and Orion Corp. announced that they have started enrolling patients for a phase III study on ODM-201.
Alnylam (ALNY) to File Clinical Trial Application for ALN-CC5 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 34 mins ago
Alnylam Pharmaceuticals (ALNY) intends to file a clinical trial application for ALN-CC5 by year end.
Gilead Down on Weak Simtuzumab Data and Sovaldi News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:16PM CDT
Shares of Gilead (GILD) were down following a couple of setbacks.
Midday Glance: Biotechnology companies
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Is It Time to Buy Dividend Stock Bristol-Myers Squibb Co?
George Budwell, The Motley Fool - Motley Fool - Thu Sep 18, 9:57AM CDT
Big Pharma's battle with the patent cliff has led to drastic changes across the healthcare sector. Companies have slashed workforces, changed the focus of their product and clinical portfolios, and even moved abroad to lower their effective tax...
ImmunoCellular Therapeutics (IMUC) Jumps: Stock Up 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:58AM CDT
ImmunoCellular Therapeutics, Ltd. (IMUC) was a big mover last session, as its shares rose nearly 9% on the day.
Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:39AM CDT
Halozyme Therapeutics, Inc. (HALO) was a big mover last session, as its shares rose over 9% on the day.
Repros Therapeutics (RPRX) Crumbles: Stock Falls by 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:51AM CDT
Repros Therapeutics Inc. (RPRX) saw a big move last session,continuing the recent downtrend for RPRX, as the stock is now down more than 11.5% in the past one-month time frame.
Gilead Sciences, inc. Stock's Incoming Game Changer
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 18, 7:45AM CDT
Gilead Sciences ' Sovaldi may have revolutionized hepatitis C treatment, but it also served as a lightning rod of controversy over drugmakers' pricing of next-generation medicines. Sovaldi's ability to clear the virus in 90% of patients over 12...
3 Best Stocks for Investing in Biotech
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 18, 7:35AM CDT
Few baskets are as hit-and-miss as biotech. The group is notoriously fickle and maddeningly volatile -- and for good reason. Whims and whispers tied to the latest clinical trial results can move biotech stocks in fits and starts, making them best...
Market Maker Surveillance Report. EPGL, CMCSA, GILD, YHOO, MSFT, VALE, Bearishly Biased Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:25AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. EP GLOBAL COMMUNICATIONS INC (OTC:EPGL), Comcast Corp (NASDAQ:CMCSA), GILEAD SCIENCES, INC. (NASDAQ:GILD), Yahoo! Inc (NASDAQ:YHOO), MICROSOFT CORPORATION (NASDAQ:MSFT), Vale SA (NYSE:VALE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Jim Cramer's 'Mad Money' Recap: Hooray for the Federal Reserve
at The Street - Wed Sep 17, 7:08PM CDT
Now that the Fed has done the right thing on monetary policy, investors should stop worrying and start thinking about how to make more money, Cramer says.
Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:15PM CDT
Merck & Co. Inc. (MRK) announced encouraging data from a pivotal phase III fracture outcomes study evaluating the use of odanacatib in postmenopausal women suffering from osteoporosis.
Shire's Vyvanse Accepted for FDA Review for Binge Eating - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:00PM CDT
Shire plc (SHPG) recently announced that the FDA has accepted its filing with priority review a supplemental New Drug Application (sNDA) for Vyvanse for treating adults with binge eating disorder.
UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:40PM CDT
UCB SA (UCBJF) and Amgen announced positive results from exploratory analyses of a phase II study on romosozumab in postmenopausal women with low bone mineral density.
Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 4:05PM CDT
Abbott Labs (ABT) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb.
